AtaiBeckley (FRA:B72) FFO


FRA:B72 AtaiBeckley Inc FRA:B72
53 GF Score
Price €4.10
GF Value €5.61
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is AtaiBeckley FFO?

FFO (Funds from operations) only applies to REITs.

FRA:B72
53GF Score
AtaiBeckley Inc FRA:B72
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AtaiBeckley (FRA:B72) Overvalued in 2026?

Based on GuruFocus' analysis, AtaiBeckley stock appears to be undervalued. The current stock price of €4.10 is trading 26.9% below its estimated GF Value™ of €5.61. GuruFocus considers AtaiBeckley to be Modestly Undervalued.

Key valuation signals for FRA:B72:

  • FFO:
  • GF Value™: €5.61 vs. price of €4.10 (26.9% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the FRA:B72 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AtaiBeckley Business Description

Other Exchanges ATAI:USAB72:Germany
Address 250 West 34th Street, New York, NY, USA, 10119
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
53GF Score

Get the complete analysis for FRA:B72

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.10
Price
€5.61
GF Value